ENCAPSULATION OF LIVING TISSUE CELLS IN A MICROSPHERE

Abstract: A process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells resulting with the gel forming solution resulting to form a mixture of a specific density. The process for encapsulating living tissue cells in a plurality of microspheres also includes the steps of mixing the mixture into a container containing an oil and stirring the mixture to form a plurality of microspheres each of which encapsulates some of the living tissue cells. The oil is immiscible with the mixture and has a lower density than the mixture.

Description: DESCRIPTION ENCAPSULATION OF LIVING TISSUE CELLS IN A MICROSPHERE Field of the Invention The field of the present invention is microsphere encapsulation of living tissue. A process for synthesizing amorphous silica microspheres is known which includes the steps of placing into a container an organosilicon precursor and with a highly acidic solution and rinsing with a solvate to remove excess of the organosilicon precursor from the amorphous silica microspheres. The organosilicon precursor and the highly acidic solution are immiscible. The process for synthesizing amorphous silica microspheres also includes the steps adding a dopant from a group consisting of rhodamine-6G, rhodamine-B, europium 3+ , fluorescein, coumarin-120, coumarin-314T, thionine, uranium and uranium-sensitized europium, stirring the organosilicon precursor and the highly acidic solution to form droplets of the organosilicon precursor in the highly acidic solution whereby water in the highly acidic solution hydrolizes the droplets of the organosilicon precursor to form amorphous silica microspheres and rinsing with a solvent to remove excess of the organosilicon precursor therefrom. The results provide fluorescence behavior. In another known process, living animal tissue cells and microbial cells such as yeast cells are encapsulated in an inorganic gel prepared from an organosilicon. Encapsulation of tissue cells is performed by mixing an organosilicon precursor with a highly acidic aqueous solution to hydrolyze the organosilicon precursor and provide a gel forming solution, cooling the gel forming solution, forming a mixture of living tissue cells and Hank's balanced salt solution, adding a base solution to the gel forming solution, immediately thereafter adding the mixture containing tissue cells to the gel forming solution, and pouring the resultant mixture into a container where an inorganic gel forms encapsulating the tissue cells. The organosilicon precursor may be tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane or tetrapropoxysilane . Microbial cells are encapsulated by a similar procedure where a gel forming solution is prepared by adding a base to a solution resulting from hydrolyzing an organosilicon with a highly acidic aqueous solution, a microbial cell dispersion is mixed with the gel forming solution and the resultant mixture is poured into a container to form an inorganic gel encapsulating the microbial cells. Summary Of The Invention The present invention is generally directed to a process for encapsulating a living tissue cell in a microsphere . The process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density. In a first separate aspect of the present invention, the process also includes the steps of mixing the mixture into a container containing an oil and stirring the mixture to form a plurality of microspheres each of which encapsulates some of the living tissue cells. The oil is immiscible with the mixture and has a lower specific density than the specific density of the mixture. In a second separate aspect of the present invention, the process also includes the steps of forming droplets of the mixture and putting the droplets into a column of an oil. The oil is immiscible with the mixture and has a lower specific density than the specific density of the mixture at the top thereof to form a plurality of microspheres each of which encapsulates some of the living tissue cells. In a third separate aspect of the present invention, the organosilicon precursor is selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane and tetrapropoxysilane. In a fourth separate aspect of the present invention, the living tissue cells are from an animal. In a fifth separate aspect of the present invention, the living tissue cells are from a plant. In a sixth separate aspect of the present invention, the living tissue cells are from fungi. In a seventh separate aspect of the present invention, the living tissue cells are from bacteria. The encapsulation of living tissue by this process creates a new drug delivery system enabling the implantation of live cells that secrete therapeutic compounds without the need for immunosuppression. Ceramic material can be used to encapsulate live tissue cells that can secrete therapeutic compounds and are implanted in a host (patient) to mimic a natural organ's delivery of therapeutic compounds. The live tissue may be genetically engineered to enhance or accomplish the desired result . The ceramic material is porous enough to allow passage of the therapeutic molecules, but the openings are small enough to isolate the implanted cells from the host's immune system. The inorganic encapsulating material is biologically inert, which reduces the risk of immune or autoimmune responses. Other aspects and many of the attendant advantages will be more readily appreciated as the same becomes better understood by reference to the following detailed description. The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. Description Of The Drawings Fig. 1 is a side elevation of a stir bar and a container which contains an oil and into which the mixture of the solution containing living tissue cells with the gel forming solution to form a mixture according to the first embodiment of the present invention. Fig. 2 is a side elevation of a dropper and a column of an oil into which the mixture of the solution containing living tissue cells with the gel forming solution to form a mixture according to the second embodiment of the present invention. Detailed Description Of The Preferred Embodiments A process for synthesizing a sol-gel encapsulating living tissue cells includes the steps of placing into a first container an organometallic precursor and a hydrolyzing solution, stirring the solution until the solution becomes clear, chilling the clear solution in an ice bath, placing into a second container living tissue cells and a balanced salt solution to form a tissue solution. Living tissue cells are harvested. The living tissue cells are placed in a balanced salt solution to form a tissue solution. The solution for human cells can be a common medical saline solution. The need is to balance sufficiently the salinity with the cells to be encapsulated to avoid rupture. U.S. Patent No. 4,797,213 teaches the use of Hanks ' balanced salt solution in column 6, line 10. The living tissue cells may be from a plant, an animal, bacteria, fungi or yeast. The organometallic precursor may be an organosilicon precursor and the hydrolyzing solution may be a highly acidic solution having a molar concentration of acid in the range of 0.05 to 2.5. The process also includes the steps of adding a base solution having a molar concentration of base in the range of 0.05 to 2.5 to the clear solution, immediately thereafter adding the tissue solution to the clear solution and the base solution, stirring the clear solution, the base solution and the tissue solution to form a gel forming solution and treating the gel forming solution to achieve the desired physical structure of the inorganic gel encapsulating the living tissue cells. The base solution is added to neutralize sufficiently the solution to avoid cell damage from an extreme pH. The organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane, tetrapropoxysilane and methyl trimethoxysilane. The organometallic precursor may be selected from a group consisting of aluminum tri-n- propoxide, aluminum tri (sec) butoxide, aluminum acetoacetic ester chelate di (sec) butoxide, zirconium tri (sec)butoxide, boron butoxide, boron methoxide, titanium (iv) butoxide, titanium isopropoxide and zirconium isopropoxide . The highly acidic solution is selected from a group consisting of nitric acid (HN0 3 ) and hydrochloric acid (HC1) . Other highly acidic solutions may also be used including sulfuric acide (H 2 S0 4) . In the preferred embodiment the base solution is ammonium hydroxide. Please refer to C. J. Brinker, Journal of Non-Crystaline Solutions, Volume 48, page 48 and Volume 63, page 45. Chapter 13 on page 141 of the book entitled Animal Cell Culture, edited by Jeffrey W. Pollard and John M. Walker and published by Humana Press which is located in Clifton, New Jersey, describes Hanks' Balanced Salt Solution. The manual entitled Plant Tissue Culture Manual : Fundamentals and Applications, edited by K. Lindsey and published by Humana Press. Tissue cells of a plant may be harvested from a leaf by grinding the leaf into leaf- fragments. The leaf-fragments are are placed in a balanced salt solution to form a plant tissue solution. Chapter 13 on page 141 of the book entitled 7Animal Cell Culture, edited by Jeffrey W. Pollard and John M. Walker and published by Humana Press which is located in Clifton, New Jersey, also describes the harvesting of tissue cells of an animal. Tissue cells of an animal may be harvested from the liver, the pancreas, the thyroid, the parathyroid, the pituitary gland and the renal cortex of mammals including man. The sol-gel which encapsulates one of these tissue cells may be used in an artificial organ such as either an artificial liver or an artificial pancreas. For example, living animal tissue cells have been harvested from beef liver (bovine hepatocytes) . The standard procedure for dispersing living animal tissue cells is to cut beef liver into small cubes. About 10 grams of the small cubes of beef liver are placed in 60 milliliters of Hanks' balanced salt solution for one half hour in order to remove the hemoglobin from the beef lever. The Hanks' balanced salt solution is removed. Forty milligrams of collagenase and sixty milligrams of dispase are dissolved in the Hanks ' balanced salt solution. Dispase and collagenase are enzymes. The Hanks ' balanced salt solution is shaken for one half hour and decented to form a tissue solution. The tissue solution is a supernatent solution which has individual living liver cells dispersed therein. The inventor has encapsulated liver cells in an organic gel. U. S. Patent No. 5,270,192 teaches a hepatocyte bioreactor, a bioartificial liver, which includes a containment vessel having a perfusion inlet and a perfusion outlet, a matrix within the containment vessel so as to entrap hepatocyte aggregates within the containment vessel while allowing perfusion of the matrix. U. S. Patent No. 4,391,909 teaches tissue cells such as islet of Langerhans cells or liver cells which are encapsulated within a spheroidal semipermeable membrane including a polysaccharide having acidic groups cross-linked with a polymer having a molecular weight greater than 3,000. The cells within the microcapsules are viable, healthy, physiologically active and capable of ongoing metabolism. The encapsulated cells are useful for implantation in a mammalian body to produce substances and effect chemical changes characteristic of the cells in vivo tissue. The inventor has encapsulated islet of Langerhans cells in an organic gel . U. S. Patent No. 5,166,058 teaches purified BMP-2 proteins which may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair. For bone and/or cartilage formation, the composition includes a matrix capable of delivering BMP-2A, BMP-2B or other BMP protein to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical DNA sequences encoding the osteoinductive proteins applications. The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the BMP-2 compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid and polyanhydrides . Other potential materials are biodegradable and biologically well defined, such as bone or dermal collagen. Further matrices consists of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics . Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. The dosage regimen will be determined by the attending physician considering various factors which modify the action of the BMP-2 protein, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical f ctors. The dosage may vary with the type of matrix used in the reconstitution and the types of BMP proteins in the composition. The addition of other known growth factors, such as IGF I (insulin like growth factor I) , to the final composition, may also effect the dosage. The biological substance of U. S. Patent No. 5,453,368 includes PC-12 cells which were cultured in standard RPMI . The cells were taken up by pipette, placed in centrifuge tubes and spun down. The cells were brought up to a volume of 2 ml, to a cell concentration of approximately 2xl0 6 to 5xl0 6 per ml. The cell containing liquid was placed in sterile Hamilton syringe and placed on a Harvard apparatus injector pump. The pump was connected via 18 gauge polytetra-fluoroethylene tubing to a 24 gauge stainless steel tube, which served as an apparatus for dropping the liquid. Microcapsules containing bovine adrenal chromaffin cells in a 1.5% sodium alginate solution (W/V) were prepared. The PBS collection bath container contained 1.5% (W/V) calcium chloride. After six weeks in culture, the microcapsules contained viable cells. The following cells have been successfully encapsulated and remained viable in silica gels using the foregoing process . In fungi : Saccharomyces cerevisiae, Phanerochaete chrysosporium. In plants : Pyrocystis lunula (photosynthetic marine algae) , Red apple ground cover leaf cells (individual chlorophyl-containing cells extracted from supernatent of ground leaves) . In bacteria: Photobacterium phosphoreum (bioluminescent marine bacteria) , Geospirillum arsenophiluf (MIT-13) , Halobacterium halobium. In animals : Murine islets of Langerhans, Porcine islets of Langerhans, Bovine hepatocytes. Porcine hepatocytes, Human white blood cells, Human red blood cells, Rat PC-12 cells (from rat pheochromocytoma) , Lac-z transfected murine mesenchymal stem cells (genetically engineed mammalian tissue cells) , Rat fibroblasts, Human fibroblasts, Human osteosarcoma cells, Chinese hamster ovarian (CHO) cells. Referring to Fig. 1 a process is disclosed for encapsulating a living tissue cell in a microsphere . The process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density. The living tissue cells are from either an animal or a plant. The process also includes the steps of mixing the mixture into a container 11 containing an oil 12 and stirring with a stir bar 13 the mixture to form a plurality of microspheres 14. Each microsphere 14 encapsulates some of the living tissue cells. The oil 12 is immiscible with the mixture and has a lower specific density than the specific density of the mixture. The organometallic precursor may be a organosilicon precursor. The organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetra-butoxysilane, tetramethoxysilane and tetrapropoxysilane . Referring to Fig. 2 a process is disclosed for encapsulating a living tissue cell in a microsphere. The process for encapsulating living tissue cells in a plurality of microspheres includes the steps of mixing an organometallic precursor and a hydrolyzing solution to form a gel forming solution, mixing living tissue cells and a salt solution to form a solution containing living tissue cells and mixing the solution containing living tissue cells with the gel forming solution to form a mixture of a specific density. The living tissue cells are from either an animal or a plant . The process also includes the steps of forming droplets of the mixture and putting the droplets into a column 111 of an oil 112. The oil 112 is immiscible with the mixture and has a lower specific density than the specific density of the mixture at the top thereof to form a plurality of microspheres. Each microsphere 114 encapsulates some of the living tissue cells. The organometallic precursor may be a organosilicon precursor. The organosilicon precursor may be selected from a group consisting of tetraethoxysilane, tetra-butoxysilane, tetramethoxysilane and tetra-propoxysilane . From the foregoing it can be seen that a sol-gel encapsulating an active biological materials, including tissue cells of an animal and micro-organisms, has been described. Accordingly it is intended that the foregoing disclosure shall be considered only as an illustration of the principle of the present invention.

Claims: Claims 1. A process for encapsulating living tissue cells in a plurality of microspheres comprising a. combining an organometallic precursor and a hydrolyzing solution to form a gel forming solution; b. combining living tissue cells and a salt solution to form a solution containing living tissue cells; c. combining the solution containing living tissue cells resulting from step b with the gel forming solution resulting from step a to form a mixture of a specific density; d. mixing the mixture resulting from step c into an oil which is immiscible with the mixture resulting from step c and has a lower specific density than the specific density of the mixture resulting from step c to form a plurality of microspheres encapsulating some of said living tissue cells. 2. The process of claim 1, the step of mixing including stirring the combination of the oil and the mixture resulting from step c. 3. The process of claim 1, the step of mixing including forming droplets of the mixture resulting from step c and putting the droplets into the top of a column of the oil. 4. The process of claim 1, 2 or 3, the organometallic precursor being an organosilicon precursor in the step of combining the organometallic precursor and the hydrolyzing solution. 5. The process of claim 4, the organosilicon precursor being selected from a group consisting of tetraethoxysilane, tetrabutoxysilane, tetramethoxysilane and tetrapropoxysilane. 6. The process of claim 1, 2 or 3 further comprising e. combining the gel forming solution resulting from step a with a base before the step of combining the gel forming solution with the solution containing living tissue cells resulting from step b to neutralize sufficiently the gel forming solution to avoid damage to the living tissue cells from an extreme pH.

Inventors: POPE EDWARD J A, POPE, EDWARD, J., A.
Applicants: SOLGENE THERAPEUTICS LLC, SOLGENE THERAPEUTICS, LLC
Application year: 1998
Main classification: C12N5
IPC codes: A61K9, A61K35, A61K47, A61L27, C12N1, C12N5, C12N11